| Name | Title | Contact Details |
|---|
NeoLife is a pioneer in whole food nutrition supplementation since 1958, with a commitment to end the trend of poor wellness and poverty.
Adamas Consulting is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AmRelieve is a multinational eCommerce business operating in the health and wellbeing industry, with a focus on serving active seniors in pain free living. They offer a range of natural health products, including CBD balms and gummies, lumbar support b...
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. At Evolus, you have the opportunity to be part of a movement. A performance beauty company changing the game. We are bringing innovation and forward-thinking technology to an industry desperately wanting frictionless experiences. Our work disrupts the status quo, but most importantly, we will make an impact, we are customer-centric - always. Because of this, we are excited to step through the door each morning. We help each other climb; we don`t climb over one another. We believe that integrity and a team-driven environment connect entrepreneurial minds. Getting goose bumps? Good. Join the Evolus movement, and let`s see where you can put your talents to work.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.